Group items tagged

Johnson & Johnson has made it to the list of top 10 most innovative companies in the world released by FOREX.com. The US-based pharmaceutical company is the fourth most innovative company, scoring 8.23/10 in the innovation index. Johnson & Johnson is the only pharmaceutical company making it to top 10 list, which makes it the world's most innovative pharmaceutical company in 2023. The ranking is based on many factors such as the number of US-registered patents in 2022, the number of R&D expenses over the last 12 consecutive months and their last reported intangible assets. The health giant spent £37.16 billion on intangible assets (the second highest after Apple), £11.87 billion on R&D last year and registered 1,377 patents last year.

US pharmaceutical giant Johnson & Johnson on Friday (November 12) announced plans to break up into two listed companies, separating its consumer health arm that sells Band-Aids and Tylenol from its pharmaceutical division. Johnson & Johnson said in a statement it will create "two global leaders that are better positioned to deliver improved health outcomes for patients and consumers through innovation." It plans to complete the separation in 18-24 months, creating two publicly traded companies. CEO Alex Gorsky said the decision was made following a "comprehensive review." The board and management believe the split is "the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities for our talented global team, drive profitable growth, and -- most importantly -improve healthcare outcomes for people around the world," he said.

Prime minister Boris Johnson received his Covid-19 booster shot on Thursday (December 2) and urged others to follow suit to help the country fend off the Omicron variant of coronavirus. Wearing a mask, Johnson briefly chatted to staff and others queuing for their shots at the vaccination centre in central London, asking them if they were there to receive a booster dose and thanking them for attending. Johnson, who said it could "have gone either way" when he was treated in hospital for Covid last year, was later filmed rolling up his shirt sleeve and receiving his shot. "Fantastic. Thank you so much," he said to the nurse, before receiving a badge that said "I've boosted my immunity".

Health secretary Sajid Javid and chancellor of the exchequer Rishi Sunak have both resigned on Tuesday (July 5) after a slew of scandals undermined the government of prime minister Boris Johnson. Javid and Sunak sent resignation letters to Johnson within minutes of each other in which both took aim at his ability to run an administration that adhered to standards. The resignations came as Johnson was apologising for appointing a lawmaker to a role involved in offering pastoral care, even after being briefed that the politician had been the subject of complaints about sexual misconduct. In his resignation letter to Johnson, Javid said "it is clear to me that this situation will not change under your leadership - and you have therefore lost my confidence too". He was appointed to lead the Department of Health and Social Care in June 2021, when his predecessor Matt Hancock quit after being caught having an affair with an adviser, in breach of social distancing guidelines.

Prime minister Boris Johnson has said he is cautious about rising cases of Covid in Europe, warning of gathering "storm clouds" of a new wave of coronavirus infections. He made the statement during a visit today (November 12) to a vaccination centre at a community pharmacy in Sidcup, London while encouraging people to come forward for Covid-19 boosters. The UK has had much higher rates of Covid-19 than the rest of Western Europe since the summer when Johnson scrapped coronavirus restrictions in England. However, rates in Britain are now coming down just as they are rising sharply in countries such as Germany, Austria and the Netherlands. Parts of Eastern Europe have also seen a sharp rise in cases.

Around 90 percent of coronavirus patients in intensive care units have not had a booster jab, prime minister Boris Johnson said on Wednesday (December 29) - defending his decision not to tighten virus curbs in England. Speaking at a vaccination centre, Johnson urged people to get "vital" booster jabs, saying "the overwhelming majority" of those currently going into intensive care in our hospitals have not had the booster jab. "I've talked to doctors who say the numbers are running up to 90 percent of people in intensive care who are not boosted," the prime minister added in Milton Keynes in Hertfordshire. Those who have not been vaccinated are "eight times more likely to get into hospital," he warned. The UK has been hit by a huge surge of the new Omicron variant, with England and Wales reporting record case numbers on Tuesday. The UK has been one of Europe's worst hit with a death toll of 148,021.

Prime minister Boris Johnson announced on Wednesday (January 19) that restrictions re-imposed in England last month would be lifted by from next Thursday (January 27). In the latest development, the government has decided to end the guidance on working from home, asking employers to make adequate arrangements to return safely to work. From the start of next Thursday, mandatory certification based on vaccines and tests will end, however, organisations can still choose to use the NHS Covid Pass voluntarily. Besides, the legal mandate to wear face masks will go away from next week. Making a statement to the House of Commons on Covid-19, he said that infection levels are falling in England mainly because of the country's "extraordinary booster campaign". He noted more than 36 million Covid-19 booster jabs had been delivered, with over 90 percent of over-60s now given a third dose. "Our scientists believe it is likely that the Omicron wave has now peaked nationally," Johnson added, while cautioning "the pandemic is not over". "I encourage everyone across the country to continue with all the cautious behaviours that we know help to keep each everybody safe."

In what's seen as a major step forward for the treatment of schizophrenia, the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised a new Johnson & Johnson drug in Britain. Byannli is a six-monthly paliperidone palmitate (PP6M) and is the first long-acting injectable schizophrenia treatment which offers patients the potential for up to six months of symptom control and a reduction in their risk of relapse with only two doses a year. It is a long-acting injectable that works by dissolving and entering the bloodstream slowly, due to its extremely low water solubility, resulting in continuous absorption of paliperidone palmitate over a six-month period. "Schizophrenia is a chronic and severe brain disorder, and antipsychotic medication plays an important role in its treatment. However, many people with the illness experience relapses which are often caused by poor adherence to oral medication," said Prof David Taylor, director of Pharmacy and Pathology at the Maudsley Hospital.

Britain on Tuesday (January 4) faced warnings of an impending hospital crisis due to staff shortages caused by a wave of Omicron infections, as the country returned to work after Christmas. However, Britain's vaccine minister said hospitalised Covid-19 patients were showing less severe symptoms than before, adding that there was no need for further restrictions at this stage. Prime minister Boris Johnson resisted imposing stringent lockdown measures in England ahead of New Year as Omicron fuelled a spike in cases to record highs. While hospitalisations are rising they have not tracked the trajectory of daily cases, possibly reflecting the impact of vaccines and booster shots, the likely lower severity of Omicron and the time lag in people going into hospital. "At the moment, if you look at the people who have been hospitalised, they are going in with less severe conditions than before," minister for Vaccines and Public Health Maggie Throup told Sky News, adding that the "Plan B" Johnson brought in in December was working. "The numbers that are in hospital beds is about half what it was a year ago - and that just shows the power of the vaccine."

Prime minister Borris Johnson visited a Boots vaccination site in his west London constituency of Uxbridge on Monday (January 10) - as the pharmacy chain celebrates its anniversary of supporting the NHS Covid-19 vaccination drive. During the visit, the prime minister met with some pharmacists who have been administering Covid-19 booster jabs to patients. Since opening the first vaccination site at its Halifax store in January 2021, Boots UK has administered over 1.4 million Covid-19 jabs, and continues to offer booster doses at over 80 pharmacies, the company said in a statement. Continuing its support for the Covid-19 booster programme, Boots has doubled appointment capacity and added a small number of new sites since December 2021. Boots vaccination programme director Nick Sunderland said: "We are so proud of our pharmacists who have worked incredibly hard to support the national effort to accelerate the Covid-19 booster vaccination programme.

Shares in GSK, Sanofi and Haleon fell sharply on Thursday (August 11) amid growing investor concerns about US litigation focused on a heartburn drug that contained a probable carcinogen, while Johnson and Johnson has decided to end sales of talcum powder after cancer claims. GSK shares were down 6.8 per cent, Sanofi's were down 6.9 per cent and Haleon's down per cent. GSK and Sanofi at various points sold the drug - originally branded as Zantac - which US regulators ordered off the market in 2020. Haleon, spun out as an independent listed company last month, comprises consumer health assets once partly owned by GSK. The prospect of impending litigation is not new. Among other disclosures, recently-listed Haleon had highlighted the risk of such lawsuits in its prospectus. The topic has arrived in investor consciousness in recent days it seems, but has been rumbling on in the background for a few years, Deutsche Bank analysts wrote in a note.

Former pharmacy minister Steve Brine was on Wednesday (November 2) elected chair of the influential Health and Social Care Committee, the cross-party parliamentary group that scrutinises the work of the Department of Health and Social Care and its associated public bodies. The Conservative MP for Winchester won 253 out of 432 votes beating off four other contenders for the role - Stephen Hammond, Dr Caroline Johnson, Anne Marie Morris and James Morris - in a four-stage election in which MPs voted by ranking candidates in order of preference. Dr Johnson, who was Mr Brine's main challenger, bagged 148 votes in the final round. An election for a new chair of the Health and Social Care Committee was triggered following the resignation of Jeremy Hunt MP who was appointment as chancellor of the exchequer on October 14. Issuing a statement after his election, Mr Brine said: "I welcome the opportunity as chair to continue the calm, measured work of Jeremy Hunt and to examine new solutions to support the NHS to enable it to continue providing the services that we all depend upon."

Charac, an NHS-integrated one-stop platform for independent community pharmacies, has secured £1 million strategic investment from the Royal Mail Group, enabling its time-saving platform to assist more local pharmacies and patients across the UK to easily manage their prescriptions and consultations online. The company said this new money will enable it to leverage strong levels of trust that pharmacists enjoy within the communities they serve in and will ensure pharmacies remain a cornerstone of vibrant high streets and an invaluable provider of frontline healthcare products and services, including vitally needed consultations. Charac says it is aiming to sign up over 1,000 UK pharmacies in the next 12 months by expanding its geographic footprint beyond current cities, including London, Manchester and Birmingham, and targeting small multiple and independent pharmacies, accounting for almost 40 per cent of the UK's community pharmacy network. The announcement also sees the addition of Stefan Kulik, a managing director at Royal Mail, to the Charac board. Stefan is responsible for leading Royal Mail's expansion into the healthcare industry and brings a breadth of experience, having previously worked in healthcare with companies including Johnson & Johnson.

Former chancellor Rishi Sunak, one of two candidates vying to be Britain's next premier, criticised the way outgoing prime minister Boris Johnson handled the Covid-19 pandemic, saying it had been a mistake to "empower" scientists and that the downsides of lockdowns were suppressed. The Tories are choosing a new leader after Johnson was forced to quit when dozens of ministers resigned in protest at a series of scandals and missteps. Party members are voting to select either Sunak or foreign secretary Liz Truss, who will take over next month. Opinion polls show Sunak is behind in race. The handling of the pandemic has become an issue, with Truss saying this month she would never again approve another lockdown and also asserting that as trade minister at the time she was not involved in taking the key decisions about how to respond. Sunak said the government had been "wrong to scare people" about coronavirus. He said he was banned by officials in Johnson's office from discussing the "trade-offs" of imposing coronavirus-related restrictions, such as the impact on missed doctor's appointments and lengthening waiting lists for healthcare in the NHS.

Covid-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months. Executives at the biggest Covid vaccine makers including Pfizer and Moderna said they believe most people who wanted to get vaccinated against Covid have already done so - more than five billion people worldwide. In the coming year, most Covid vaccinations will be booster shots, or first inoculations for children, which are still gaining regulatory approvals around the world, they said. Pfizer, which makes its shot with Germany's BioNTech and Moderna still see a major role for themselves in the vaccine market even as overall demand declines. Upstart US vaccine maker Novavax and Germany's CureVac, which is working with GlaxoSmithKline, are developing vaccines they hope to target at the booster market. The roles of AstraZeneca and Johnson & Johnson, whose shots have been less popular or effective, are expected to decline in this market.

Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion (£22.67bn), fortifying its rare diseases portfolio in the biggest buyout in the sector this year. The company will pay $116.50 in cash, a premium of nearly 20 per cent to the stock's last close, for each Horizon share. Horizon shares closed up 15 per cent on Monday at $112.36. They had climbed 23.5 per cent through Friday since the company disclosed in late November it was in preliminary talks with Amgen, Sanofi and Johnson & Johnson for potential offers. Amgen shares dipped less than 1 per cent to close at $276.78. Sanofi said Sunday it ended discussions with Horizon after concluding the transaction prices "do not meet our value criteria." J&J also said in early December that it had dropped its pursuit of the deal.

Despite the government's announcement on lifting most Covid-19 related restrictions from next Thursday (January 27), people working in community pharmacies will be required to adhere to the UK Health Security Agency's infection prevention control (IPC) guidance. The ambit the guidance, which aims to protect everyone against the infection, also covers GP practices, dental practices and optometry practices, the Pharmaceutical Services Negotiating Committee said in an update. The negotiators also urged community pharmacy teams to encourage patients to wear a face covering while vising pharmacy to keep staff and other patients safe. Prime minister Boris Johnson announced on Wednesday (January 19) that Covid-19 restrictions re-imposed in England last month would be lifted by from next Thursday (January 27).

Provision of free lateral flow tests could end in the UK, and prime minister Boris Johnson is expected to make the big announcement within weeks, The Sunday Times has reported. The report said that in future free test kits could be provided only in high-risk settings such as care homes, hospitals and schools, and to people with symptoms, and contact tracing by NHS Test and Trace is also expected to be scaled back. The newspaper quoted a senior Whitehall source as saying: "I don't think we are in a world where we can continue to hand out free lateral flow tests to everybody. "It's likely we will move to a scenario where there is less testing, but we have a capacity to ramp it up if necessary." It added that more than £6 billion of public money has already been spent on mass testing. Separately, Dr Clive Dix, former chairman of the country's vaccine task force said that Covid-19 should now be treated as a flu, and mass vaccination campaigns should end after the booster shots in the UK.

Britain on Monday (January 10) put the biggest private health companies on high alert to deliver crucial treatments such as cancer surgery should Omicron overwhelm National Health Service hospitals in England. The United Kingdom's death toll from the Covid-19 pandemic stands at 150,154, the world's seventh worst official Covid toll after the United States, Brazil, India, Russia, Mexico and Peru. Prime minister Boris Johnson has bet on refraining from lockdowns to deal with the Omicron variant which in recent weeks has swept across the UK, albeit with death rates significantly lower than previous waves. In a sign of just how stretched the NHS could become, health secretary Sajid Javid ordered England's NHS to strike a three-month deal with private health companies to allow patients to get treatments such as cancer surgery outside. "Millions of patients have already got their tests and treatment quicker thanks to our existing deal with independent providers," said David Sloman, NHS England chief operating officer and Covid incident director.

Britain will offer a Covid-19 booster shot to all adults and could halve the dose interval for booster jabs from six to three months in a bid to accelerate its vaccination programme amid concern over the new Omicron coronavirus variant, as number of new cases found in the country rise. The move, backed by a scientific advisory body and Health Secretary Sajid Javid, comes as ministers scramble to react swiftly to the new variant, which was first detected in South Africa. Prime minister Boris Johnson has responded to the emergence of Omicron by making mask-wearing compulsory in shops and on public transport in England. Until now, only adults in the UK aged 40 and above were eligible for a booster dose six months after their last. But that timeframe will now be halved to three months, alongside the programme's expansion to all over-18s, with priority given to older people. "These measures will protect more people, more quickly and make us better protected as a nation," Javid told MPs.